Overview

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis
Phase:
Phase 2
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.